Company intelligence / Profile preview

ALOHA

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Aloha Therapeutics is a clinical-stage biotechnology company focused on developing mucosal immunology treatments for respiratory viral infections. The company's lead candidate is a low-dose, orally administered formulation of interferon-alpha designed to stimulate the innate immune system in the upper respiratory tract. By targeting the site of initial viral entry, Aloha aims to provide a broad-spectrum prophylactic and therapeutic solution for viruses such as SARS-CoV-2 and influenza. The approach leverages established cytokine biology in a novel delivery format to enhance safety and accessibility.

Therapeutic areas: Infectious Diseases
Modalities: CytokineProteinRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on ALOHA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALOHA.

Explore the full profile